uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV Investors Conference Call Transcript

Jun 23, 2022 / 12:30PM GMT
Release Date Price: $19.15 (+25.66%)
Operator

Good day, and thank you for standing by. Welcome to uniQure's AMT-130 Huntington's Disease Program Update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker to Maria Cantor, Chief Corporate Affairs Officer. Please go ahead.

Maria E. Cantor
uniQure N.V. - Chief Corporate Affairs Officer

Good morning, and thank you for joining us. This morning, uniQure announced safety and biomarker data on 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease.

6 of these 10 patients received AMT-130 and 4 patients experienced an imitation surgical procedure in this randomized blinded study being conducted in the United States. Observations shared today pertain to safety, tolerability and biomarker data at 12 months following AMT-130 administration.

Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer; and Dr. Ricardo Dolmetsch, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot